Dermatology News will be on site later this week at the annual meeting of the American Academy of Dermatology in Orlando. Look for the latest news in medical, surgical, and aesthetic dermatology starting Friday, March 3. The late-breaker sessions are on Saturday and Sunday March 4 and 5.
The late-breaking research session on clinical trials on March 4 will highlight:
- 16-week results from two phase III studies of certolizumab for chronic plaque psoriasis.
- Phase III results on the long-term management of moderate to severe atopic dermatitis (AD) with dupilumab plus topical corticosteroids.
Additional late breakers focus on pediatric, procedural, and pathology studies:
- Data from the Pediatric Eczema Elective Registry, on racial/ethnic disparities in health care utilization and school attendance among children with AD.
- Results of a prospective study evaluating the efficacy and systemic absorption of topical timolol for infantile hemangioma.
- Results of a randomized, placebo-controlled, double-blind study of oral tranexamic acid for treating moderate to severe melasma.
- The efficacy of adjuvant treatment with the long-pulsed 1064nm Nd:YAG Laser for toe onychomycosis.
- Risk factors associated with a recent change in the size, shape or color of moles among participants in the AAD SPOTme® Program (2009-2010).
- A survey-based study on the management of longitudinal melanonychia among attending and resident dermatologists.